Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT06861634

Optimization of Morphinomimetic Administration Intraoperatively: Evaluation of the Impact of the NOL Index on the Occurrence of Postoperative Adverse Events Related to Morphinomimetics

Optimization of Morphinomimetic Administration Intraoperatively: Evaluation of the Impact of the NOL Index on the Occurrence of Postoperative Adverse Events Related to Morphinomimetics: A Randomized Controlled Trial

Status
Not Yet Recruiting
Phase
N/A
Study type
Interventional
Enrollment
332 (estimated)
Sponsor
University Hospital, Tours · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Reducing the quantity of morphinomimetics during the operative period reduces the prevalence and intensity of adverse effects. However, morphinomimetics are indispensable during surgery, as they limit the autonomic nervous system's deleterious reactions to nociception. The administration of these drugs in intravenous boluses during surgery is usually guided by their duration of action and by variations in heart rate and blood pressure. Other events, such as hypovolemia or extreme surgical position, may stimulate the autonomic nervous system outside of nociception. These events, along with routine drug administration, can lead to undue consumption of morphinomimetics. The Nol index, a multiparametric monitor of nociception, is based on analysis of variations in plethysmography waveform, heart rate and skin conductance. It has been demonstrated that the use of this type of monitor can reduce intraoperative consumption of morphinomimetics and optimize their administration. Does intraoperative morphinomimetic administration optimized by the NOL index have an impact on the occurrence of dose-dependent adverse effects?

Conditions

Interventions

TypeNameDescription
PROCEDURENol indexMorphinomimetics will be administered according to NOL Index values or according to the usual criteria.

Timeline

Start date
2025-03-01
Primary completion
2028-04-01
Completion
2028-04-01
First posted
2025-03-06
Last updated
2025-03-06

Locations

6 sites across 1 country: France

Source: ClinicalTrials.gov record NCT06861634. Inclusion in this directory is not an endorsement.